Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com

Immunic (NASDAQ:IMUX) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Brookline Capital Management reissued a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Friday, April 5th.

Immunic Stock Performance

Immunic stock opened at $1.22 on Friday. Immunic has a one year low of $0.95 and a one year high of $3.11. The stock has a market cap of $109.90 million, a PE ratio of -0.58 and a beta of 2.07. The stock has a 50-day moving average of $1.33 and a two-hundred day moving average of $1.26.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.03. As a group, sell-side analysts predict that Immunic will post -0.99 EPS for the current fiscal year.

Institutional Trading of Immunic

A number of institutional investors have recently made changes to their positions in the company. RTW Investments LP boosted its stake in shares of Immunic by 0.9% in the third quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after acquiring an additional 40,796 shares during the last quarter. Gratus Capital LLC boosted its stake in Immunic by 15.1% during the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after buying an additional 254,999 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Immunic by 26.8% during the third quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock worth $1,111,000 after buying an additional 159,973 shares during the last quarter. Sierra Summit Advisors LLC purchased a new stake in Immunic in the fourth quarter valued at $487,000. Finally, Innovis Asset Management LLC raised its position in Immunic by 46.3% in the third quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock valued at $401,000 after purchasing an additional 86,217 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.